Release issued 6th November 2009

DSM Pharmaceutical Products
DSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries. DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), fermentation, mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticals.com.

Royal DSM N.V. creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM’s products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing. DSM has annual net sales of EUR 9.3 billion and employs some 23,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information: www.dsm.com


Galenix
Founded in 1993 by CEO Jérôme Besse, Galenix is ranked in the top European leaders for Drug Product Development, drug delivery systems and Clinical services. Galenix provides comprehensive pharmaceutical development services to healthcare companies, from the sourcing of Active Pharmaceutical Ingredients (API’s) to clinical supply services and regulatory submission. Its two major competitive strengths, in addition to a full pharmaceutical service delivery, are the compliance of the cGMP facilities with European and American standards, as well as its extensive expertise and experience in patented innovative drug delivery system design and drug product development.
The Galenix drug delivery systems, providing improvement and better patient compliance of medicines, include Minextab® and Minextab Floating® high dosage tablet technologies, Microgix® bioavailability / solubility technology, Mucolys Film®, a transmucosal absorption and Mucolys Flash® sub-lingual absorption technologies and the ODTx® orodispersible / dispersible oral dosage technology with no need of water to ingest.
More information: www.galenix.fr



Galenix, a key pharmaceutical R&D partner, helps Customers to reduce timeline by offering innovative solutions

Every day, Galenix is investing in innovative solutions and technologies, optimizes the drug product development process allowing its Clients to introduce a marketing difference and improvement of the Patient compliance.
Galenix is innovative, flexible and delivers quality products and services to its Clients on time. Its main focus is to satisfy the Customer according to its strategic needs.

Galenix is an ideal strategic partner for outsourcing pharmaceutical development and innovative drug product acquisitions, with a full range of services for each stage of pharmaceutical development process from preformulation, analytical and formulation development through clinical trial supplies for Phase I, II and III to scale up and high volume pilot production.
Its offer is customisable depending on the needs and the requirements of the Clients.


For more information:
GALENIX
Jerome BESSE
CEO
Tel: +33 5 56 68 83 00
Email: jbesse@galenix.fr